

PNC-28

Cat. No.:	HY-P3509
CAS No.:	392661-17-5
Molecular Formula:	C ₁₆₄ H ₂₅₅ N ₄₇ O ₃₇ S
Molecular Weight:	3509.13
Sequence Shortening:	ETFSDLWKLLKKWKMRNQFWVKVQRG
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research ^{[1][2]} .	
In Vitro	PNC-28 (0-0.5 mg/mL) blocks growth of a lethal human pancreatic cancer cell line ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay ^[2]	
	Cell Line:	MiaPaCa-2 human pancreatic carcinoma cells
	Concentration:	0.1, 0.3, and 0.5 mg/mL
	Incubation Time:	daily
	Result:	Showed dependent induction of tumor cell death starting at 0.1 mg/ml.
In Vivo	PNC-28 (2 mg/mouse, SC or IP, for 14 days) blocks the growth of BMRPA1. Tuc3 cells in vivo ^[1] . PNC-28 (1-20 mg/mouse, SC, for 14 days) inhibits BMRPA1. Tuc3 tumor growth especially if delivered directly to the tumor ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells) ^[1]
	Dosage:	2 mg/mouse
	Administration:	Implanted s.c. or i.p., with 14 days mini-osmotic pumps releasing PNC-28 at a rate of 0.25 µl/hr
	Result:	No ascites was seen in the PNC-28-treated animals. strongly effective in inhibiting this particular tumor.
	Animal Model:	Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells) ^[1]

Dosage:	1 mg/mouse, 10 mg/mouse and 20 mg/mouse
Administration:	When the tumors reached sizes from 40 to 260 mg/mouse, mini-osmotic pumps were implanted s.c. that released, over a period of 14 days
Result:	Resulted in a significant level of tumor growth inhibition in a dose-related manner.

REFERENCES

- [1]. Michl J, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. *Int J Cancer*. 2006 Oct 1;119(7):1577-85.
- [2]. Kelley A. Sookraj. QS304. Novel p53-Derived Peptide Induces Rapid Human Pancreatic Cancer Cell Death. 2008, 144(2), 1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA